DDInter1628 DDInter1379
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Escitalopram
Escitalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Palbociclib
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palbociclib
Ruxolitinib {u} (Compound) binds {v} (Gene) PLK3
PLK3 {u} (Gene) is upregulated by {v} (Compound) Irinotecan
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palbociclib
Ruxolitinib {u} (Compound) binds {v} (Gene) BMP2K
BMP2K {u} (Gene) is bound by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palbociclib
Ruxolitinib {u} (Compound) binds {v} (Gene) IRAK1
IRAK1 {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palbociclib
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Palbociclib
Ruxolitinib {u} (Compound) binds {v} (Gene) PLK1
PLK1 {u} (Gene) is downregulated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Palbociclib
Ruxolitinib {u} (Compound) upregulates {v} (Gene) FOXJ3
FOXJ3 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palbociclib
Ruxolitinib {u} (Compound) upregulates {v} (Gene) WAPAL
WAPAL {u} (Gene) is downregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palbociclib
Ruxolitinib {u} (Compound) binds {v} (Gene) PHKG2
PHKG2 {u} (Gene) is upregulated by {v} (Compound) Rifabutin
Rifabutin {u} may lead to a major life threatening interaction when taken with {v} Palbociclib
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Escitalopram (Compound) and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Ruxolitinib (Compound) binds PLK3 (Gene) and PLK3 (Gene) is upregulated by Irinotecan (Compound) and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Ruxolitinib (Compound) binds BMP2K (Gene) and BMP2K (Gene) is bound by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Ruxolitinib (Compound) binds IRAK1 (Gene) and IRAK1 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Palbociclib
Ruxolitinib (Compound) binds PLK1 (Gene) and PLK1 (Gene) is downregulated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Palbociclib
Ruxolitinib (Compound) upregulates FOXJ3 (Gene) and FOXJ3 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Ruxolitinib (Compound) upregulates WAPAL (Gene) and WAPAL (Gene) is downregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Ruxolitinib (Compound) binds PHKG2 (Gene) and PHKG2 (Gene) is upregulated by Rifabutin (Compound) and Rifabutin may lead to a major life threatening interaction when taken with Palbociclib